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Summary:
Infections are a major cause of morbidity and mortality in
patients undergoing high-dose therapy and allogeneic bone
marrow transplantation (BMT) despite prophylaxis, use
of growth factors and newer antimicrobial drugs. We
report the clinical profile of infections among 297 patients
who underwent 304 allogeneic transplants between 1986
and December 2001. All patients developed febrile
neutropenia. There were 415 documented infections
among 304 transplants. This included bacterial (34.9%),
viral (42.9%), fungal (15.9%) and other infections (6.3%)
including tuberculosis. Bacterial pathogens were mainly
Gram-negative bacteria (80%) as compared to Gram-
positive (20%) bacteria. The common Gram-negative
bacteria were nonfermenting Gram-negative bacteria
(NFGNB) (24.9%), Pseudomonas (17.9%), Escherichia
coli (17.9%) and Klebsiella (9.7%). The major source of
positive cultures was blood (53.7%) followed by urine
(25.5%) and sputum (8.9%). In all, 133/304 (43.7%)
transplants had 178 documented viral infections. The
common viral infections were due to cytomegalovirus,
herpes group of viruses and transfusion-related hepatitis;
and 60/304 (19.7%) transplants had 66 documented
fungal infections. Common fungi included Aspergillus
species (69.7%), Candida (22.2%) and Zygomycetes
(8.1%). Tuberculosis was documented in 2.3% of the
transplants. Catheter infections were suspected or docu-
mented in 7.8% of the transplants (24/304). The incidence
of infections in this series from developing countries is not
significantly different from reports from the West.
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Infections following allogeneic bone marrow transplanta-
tion (BMT) contribute to morbidity and mortality in the
peri and post transplant period. During the first 30 days
after BMT, sepsis is mainly related to neutropenia,
mucositis and reactivation of dormant herpes simplex.
Acute graft-versus-host disease (GVHD) and therapy for
GVHD contribute to sepsis in the 30–100 day period.
Following this, delayed immune reconstitution contributes
to Gram-positive infections. Host defenses are profoundly
altered due to the conditioning regimen, use of implanted
venous catheters, administration of prolonged immuno-
suppressive drugs and reactivation of infection. Bacterial
and fungal infections in the post transplant period
contribute to 15% of post transplant mortality. There is a con-
cern that transplants in developing countries may be asso-
ciated with a higher incidence of infections related to the
poor quality of the environment around the transplant center.
We have attempted to look at the pattern of infections in
our center over the past 15 years and compare this data
with published literature from the Western world.
Patients and methods
All patients who underwent allogeneic BMT at the
Christian Medical College Hospital between October 1986
and December 2001 were included in this study. The
medical records of these patients were analyzed for data
pertaining to infection including cultures, biopsy and
autopsy reports. All patients had six antigen HLA-matched
sibling or family donors.
Transplant
All patients were nursed in HEPA-filtered rooms. Water
used for the patient and the unit was boiled and cooled.
Food for the patient was usually terminally pressure-
cooked prior to consumption. Dual lumen Hickman
Broviac catheters inserted surgically under general anaes-
thesia acted as venous accesses. These venous catheters
were dressed twice a week from insertion till discharge from
Vellore by trained nursing staff. Once the patient was
discharged from the hospital, they remained in Vellore for a
period of 4–8 weeks in apartments/houses close to the
hospital for easy access.
Antimicrobial prophylaxis. Acyclovir was administered at
the dose of 15mg/kg/day intravenously starting on day þ 1
and switched to oral by day 14. This was continued for
3–6 months as cytomegalovirus (CMV) prophylaxis.
Sulfamethoxazole/Trimethoprin for Pneumocystis carinii
prophylaxis was started once the WBC count was
above 3000/mm3 with an ANC 41500/mm3. Intravenous
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immunoglobulin (i.v.Ig) was administered at a dose of
400mg/kg on day þ 7, þ 21, and subsequently was given
monthly for affordable patients till 12 months post BMT.
GVHD prophylaxis consisted of Cyclosporine (2.5mg/kg/
day i.v.) from day 4, while short-course Methotrexate
was administered on days þ 1, þ 3, þ 6 and þ 11 post
BMT followed by folinic acid rescue.
Documentation of infection
The patient was considered to be febrile if a body
temperature of X38.21C was documented.
Bacterial infections: Bacterial infections were documen-
ted on positive culture from any sites – blood, urine,
sputum, pus, abscess and catheter. Urine culture was
considered to be significant if the colony count was more
than 100 000/mm3 or if colony counts o100 000/mm3, but
considered to be significant if the patient was already on
antibiotics. Sputum culture was significant in the presence
of pulmonary findings or X-ray infiltrates.
Fungal infections: All fungal infections were documented
as probable, possible and proven fungal infections based
upon the CDC criteria.1
Viral infections: The diagnosis of herpes simplex and
zoster was made on clinical grounds, while tissue invasion
was proven on biopsy and histology. The diagnosis of
invasive CMV disease was based on tissue diagnosis. PCR
for CMV antigen was carried out by day þ 30 for all
patients since 1998. Adenovirus detection was based on
ELISA.
Tuberculosis: The diagnosis of tuberculosis was based on
biopsy showing granulomas positive for AFB and/or
cultures being positive.
Antimicrobial therapy
Broad-spectrum antibiotics were started immediately after
the temperature rose above 38.21C or higher or for
documented or suspected bacterial infections. Blood
cultures were drawn prior to the initiation of antibacterial
therapy. X-ray examination of the chest was also carried
out. Our first-line antibiotic therapy for febrile neutropenia
consists of cefotaxime, gentamicin and fluconazole. If the
fever persists or the patient is toxic, this is rapidly escalated
to ceftazidime or imipenem and amoxycillin/calvulinic acid
or vacomycin. Fluconazole is changed to amphotericin if
fever persists or in the presence of pulmonary infiltrates.
Stool and throat surveillance cultures were performed once
a week and guide antibiotic policy, particularly if there are
resistant bacteria. Ganciclovir was started if the patient
became PCR positive for CMV and was on immuno-
suppressive therapy for the treatment of acute GVHD.
Results
A total of 297 patients had 304 allogeneic transplants
between October 1986 and December 2001. This included
211 males (69.4%) and 93 females (31.6%). Recipients
included 164 children (o15 years) and 140 adults with an
average age of 17.3 years (range: 0.5–51 years). The graft
source was bone marrow in 266/304(87.5%), G-CSF-
mobilized stem cells in 37/304(12.1%) and cord blood in
one patient (0.4%). Indications for BMT include thalas-
saemia major (50.8%), acute lymphoblastic leukemia
(14.7%), chronic myeloid leukemia (13.1%), aplastic
anemia (11%), acute myeloid leukemia (4.2%), myelodys-
plastic syndrome (4.7%) and others (including PNH,
PRCA, DBA) (1.5%).
Infections: There were 415 documented infections in 304
transplants. This included 145 bacterial (34.9%), 178 viral
(42.9%), 66 fungal (15.9%) and 26 other infections (6.3%).
There was no difference in the incidence of infections
between patients transplanted for malignant and nonma-
lignant indications. Fungal infections were, however, seen
to be lower among pediatric patients as compared to adults
(Table 1).
Bacterial infections: In all, 111/304 (36.5%) transplants
had 145 documented bacterial infections. The majority of
bacterial infections (55%) occurred in the first 30 days
following BMT. The organisms identified were mainly
Gram-negative bacteria (80%) with few Gram-positive
organisms (20%) (Table 2). The common gram-negative
bacteria identified included NFGNB (24.9%), Pseudomonas
(17.9%), E. coli (17.9%) and Klebsiella (9.7%).The gram-
positive organisms were Staphylococcus aureus (5.5%) and
Coagulase negative staphylococci (8.9%). Positive bacter-
iological cultures were obtained from blood (53.7%)
followed by urine (25.5%) and sputum (8.9%) (Table 3).
Majority of the organisms causing bacteremia were gram-
negative organisms (81%), commonly NFGNB and Pseu-
domonas. The overall incidence of bacterial infections seems
to be slowly decreasing over the years, although infections
by gram-positive organisms seems to be slowly increasing
(31.1% after 1996 compared to 9.6% between 1991 and
1995).
Viral Infections: In all, 133/304(43.7%) transplants had
178 documented viral infections (Table 4). The common
pathogens include CMV, herpes group of viruses, adeno-
virus and transfusion-related hepatitis viruses.
Table 1 Patient profile and distribution of infection
Bacterial infections Viral infections Fungal infections
Overall (n¼ 304) 111 (36.5%) 133 (43.7%) 60 (19.7%)
Malignant disorders (n¼ 113) 43 (38.1%) 45 (39.8%) 24 (21.2%)
Nonmalignant disorders (n¼ 191) 68 (35.6%) 88 (46%) 36 (18.8%)
Adults (n¼ 140) 50 (35.7%) 56 (40%) 40 (28.5%)
Children (n¼ 164) 61 (37.1%) 77 (46.9%) 20 (12.1%)
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CMV: CMV infection was detected in 69/304 (22.6%) of
transplants. Of these, 56/69 (81.1%) patients were positive
for CMV by PCR. CMV disease was confirmed by biopsy
in 16/69 (23.1%). Sites of involvement included gastro-
intestinal tract (31.2%), lungs (25%), liver (6.3%) and also
a disseminated form (37.5%). CMV infection was docu-
mented at a median of 48 days post transplant (pre BMT –
121 days). Documented CMV infection was seen mainly in
patients on immunosuppressive medication for acute
GVHD. Among the 16 patients who had documented
CMV disease, nine (56%) have expired.
Herpes simplex and zoster infection: Herpes simplex
infection was seen in 37/304 (12.1%) transplants. The
majority (87%) had only oral herpes simplex. Tissue
infiltration was seen in the GIT and as genital ulcers.
Herpes zoster was seen in 15/304 (4.9%) of the transplants.
The average time of infection was 133 days (day 3 to 365
days).
Hepatitis B infection: Hepatitis B was detected in 17/304
(5.5%) of transplants. In 9/17 (52.9%), hepatitis B was
diagnosed prior to BMT, while in 8/17 (47.1%), hepatitis B
infection was diagnosed after BMT. In all, one patient died
of hepatic encephalopathy related to hepatitis B; two
patients had donors who were hepatitis B positive (HbSAg
positive but HBV DNA negative), but there was no
seroconversion post BMT in both the patients.
Hepatitis C infection: Hepatitis C was detected in 30/304
(9.8%) transplants. In all, 25/30 (83.3%) patients
were positive for Hepatitis C prior to BMT, and 5/30
(16.7%) developed Hepatitis C following BMT. There
was no worsening of hepatic dysfunction attributable to
Hepatitis C.
Adenovirus infections: Adenoviral infections were seen in
6/304 (1.9%) of all transplants. Adenovirus was isolated
from urine in four (66.6%) and one each from lungs and
stool. Almost all patients had a self-limiting illness, except
for the patient with adenoviral pneumonia where it was
fatal.
Fungal infections: Fungal infections were documented in
60/304 (19.7%) transplants. The common organisms
identified were Aspergillus species (69.7%), Candida species
(22.2%) and Zygomycetes (8.1%). For infections due to
aspergillus, all patients fulfilled the CDC criteria of either
proven or possible fungal infection. Majority of the
infections were seen in the early and mid recovery phase
of BMT (o100 days post BMT). Only a few (12%)
occurred more than 100 days post BMT with all being on
chronic immunosuppressive therapy for GVHD. The most
common site of fungal infection was the lung (51.5%).
Other sites included the central nervous system, isolation
from blood (candida), gastrointestinal tract, skin, catheter
related and a disseminated form (Table 5).
Tuberculosis: In total, 9/304 (2.3%) of transplants
developed tuberculosis. This included a disseminated form
in five (55.5%), involvement of the bone in two patients
(22.2%) and involvement of the lung and the lymph node in
one patient each. All patients were on steroids for GVHD
when they developed tuberculosis. All patients have
responded well to antituberculous therapy.
Parasitic Infections: Two patients had infections with
Plasmodium vivax and one with Plasmodium falciparum
infection during BMT. All patients were treated success-
fully. Cryptosporidium was identified in the stool in nine
patients (2.9%). Ascaris infection was seen in four patients
(1.3%). Infections due to P. carinii infections were not seen
in any transplant recipients.
Catheter-related infections: In all, 24/304 (7.8%) trans-
plants had either suspected (55%) or documented (45%)
catheter infections. Organisms included Staphylococcus
aureus (45.4%), Coagulase negative staphylococci (27.3%)
and Candida albicans (27.3%).
Table 2 Bacterial infections – organisms identified
Gram-negative organisms 116 (80%) Gram-positive organisms 29 (20%)
Nonfermenting GNB 36 (24.8%) Coagulase negative staphylococci 13 (8.9%)
Pseudomonas 26 (17.9%) Staphylococcus aureus 8 (5.5%)
Escherichia coli 26 (17.9%) Enterococcus 5 (3.5%)
Klebsiella 14 (9.7%) Others 3 (2.1%)
Others 14 (9.7%)
Table 3 Bacterial infections – sources of positive culture
Blood 78 (53.7%)
Urine 37 (25.5%)
Sputum 13 (8.9%)
Pus 5 (3.5%)
Catheter site 4 (2.8%)
Others 8 (5.6%)
Table 4 Viral infections – pathogens
Cytomegalovirus 69 (38.8%)
Herpes simplex 37 (20.8%)
Hepatitis C 30 (16.8%)
Hepatitis B 17 (9.5%)
Herpes zoster 15 (8.4%)
Adenovirus 6 (3.3%)
Others 4 (2.4%)
Table 5 Sites of fungal infection
Lungs 34 (51.5%)
Disseminated 10 (15.5%)
GIT 5 (7.5%)
Blood 4 (6.0%)
CNS 4 (6.0%)
Others – skin, catheter, sinus, heart, ear 9 (13.5%)
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Mortality: Out of 304 transplants, 120 (39.4%) have
expired, with 84 (27.6%) expiring in the first 100 days
following BMT. Infection-related 100-day mortality was
seen in 45 out of the 304 transplants (14.8%) The major
causes included fungal pneumonia and CMV infection
(Table 6).
Discussion
Infections are a major cause of morbidity and mortality in
patients following allogeneic BMT. In our study, we have
tried to evaluate the clinical profile of various infections
following allogeneic BMT, and ascertain whether infections
following BMT in a developing country in the tropics were
similar to economically advanced countries.
In all, 251/304(82.5%) transplants had clinical or
microbiologically significant bacterial, fungal or viral
infection with all patients developing febrile neutropenia.
The incidence rates reported in western studies have varied
between 60 and 90% depending on the transplant center.2
The incidence of bacterial infections of 36.5% is similar
to western data3,4 where rates ranging between 35 and 50%
have been reported. Gupta et al5 from a referral center in
North India have reported similar infection rates among
transplant patients. Data from developing countries though
limited are similar, with 40–50% of patients developing
bacterial infections.6 Gram-negative bacteria are still the
major organisms, although recently the incidence of gram-
positive organisms seems to be on the increase, consistent
with western data.7 The decrease in the incidence of
documented bacterial infections related to early and
aggressive use of antibiotics in treating febrile neutropenia
in transplant recipients has also reflected in a decreased
mortality attributable to bacterial infections over the
years.3,4,7
Viral pathogens seem to be the major organisms causing
infections among Indian transplant recipients. The inci-
dence of herpes simplex and herpes zoster infections (8–
10%) are similar to incidences worldwide.8,9 CMV infection
was common (38.8%), with histological or microbiological
evidence of CMV disease seen in 9.5% of patients. Limited
data from Asia reveal incidences varying from 1.7 to 16%,
although CMV is the main causative organism associated
with interstitial pneumonitis (36–60%).10,11 Early diagnosis
of CMV antigenemia using PCR and preemptive therapy
with ganciclovir, especially in patients ‘at risk’, may help in
reducing the risk of CMV disease.12,13
The incidence of hepatitis B and hepatitis C seems to be
similar to western data.14,15 Reactivation and hepatic
dysfunction due to hepatitis B or C was uncommon among
transplant recipients. Reactivation can be seen in 8–12% of
patients with hepatitis B during BMT and rare case reports
exist with hepatitis C. The use of HbSAg-positive, but HBV
DNA-negative donors did not result in seroconversion in
any of our patients.
Data on fungal infections from various transplant
centers around the world suggest an incidence varying
between 4 and 30%.16,17 Studies from Asian countries like
Israel have observed an increasing incidence of fungal
isolates from BMT units18 similar to the data from our
center (19.7%). Infections due to Candida infections have
decreased over the years probably due to the early
institution of fluconazole for the treatment of febrile
neutropenia. Invasive fungal infections due to aspergillus
are still a major cause of morbidity affecting 14.5% of
transplants. Steroid therapy for GVHD and prolonged
neutropenia secondary to graft failure or rejection were
identified as the main predisposing factors19,20 in the
majority of fungal infections.
Tuberculosis was surprisingly uncommon (2.3%) among
transplant recipients.21 Studies from developing countries,
including Turkey and Hong Kong, have reported inci-
dences varying between 1 and 12%.22–24 In view of the low
incidence in India, INAH prophylaxis during BMT may
not be essential.
Parasitic infections including malaria seem to be
uncommon, despite India being endemic for malaria. There
were no reported infections due to P carinii in our series,
although worldwide data suggest an incidence varying
between 2 and 7%.25 Early initiation of Septran prophy-
laxis may have helped in this observation. Catheter-related
infections are less common (7.8%) compared with the
available data where the incidence varies from 12 to 40%.26
This may be related to the aggressive catheter care practised
by our nursing staff for all transplant recipients.
This study demonstrates that it is possible to perform
BMT in the developing world with infection rates compar-
able to the western world. Despite the poor quality of the
environment, contaminated water and poor sanitation as
seen in many developing countries, the overall infection
rates are not higher, suggesting that there may be enough
immune recovery to prevent infections unless there is
GVHD. Institution and adherence to a well-planned
infection control strategy for the transplant units and an
appropriate strategy for the prevention and management of
sepsis may also have contributed to this decrease.
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